European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: The example of breast cancer

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 38, Issue , 1996, Pages

  Antoine, Eric C ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Breast cancer; Dose intensification; Granulocyte growth factors; Peripheral blood stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; MELPHALAN; METHOTREXATE; THIOTEPA; VINCRISTINE;

BREAST CANCER; CLINICAL PROTOCOL; CONFERENCE PAPER; FEMALE; HUMAN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL;

EID: 0029814621     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051049     Document Type: Conference Paper

References (71)

1. Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei E III (1992) A phase II study of high dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10: 102
2. Antman K, Corringham R, Vries E de, Elfenbein G, Gianni AM, Gisselbrecht C, Herzig R, Juttner C, Kaizer H, Kennedy MJ, Kessinger A, Kotasek D, Lazarus H, Ljungman P, Maranichi D, Nabholtz J, Niederwieser D, Ogawa M, Patrone F (1992) Dose intensive therapy in breast cancer. Bone Marrow Transplant 10: 67
3. Ayash LJ, Elias A, Wheeler C, Reich E, Schwartz G, Mazanet R, Tepler I, Warren D, Lynch C, Gonin R, Schnipper L, Frei E III, Antman K (1994) Double dose intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 12: 37
4. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei E III, Elias A (1995) Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13: 2043
5. Baker WJ, Vukelja SJ, Burrell LM, Perry JJ (1994) High-dose cyclophosphamide (CY), etoposide (VP-16), and carboplatin (CBCA) with autologous bone marrow transplantation (ABMT) in the treatment of metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 13: 99
6. Bearman SI, Jones RB, Shpall EJ, Stemmer SM, Myers SE, Purdy M (1994) High-dose chemotherapy (HDCT) with autologous progenitor cell support (APCS) for stage IV NED breast cancer (abstract). Proc Am Soc Clin Oncol 13: 98
7. Beretta G, Abiadon D, Tedeschi L, Gambrosier P, Beretta GD, Luporini G (1986) Therapeutic response after two dose levels of intravenous CMF in metastatic breast carcinoma (abstract). Proc Am Soc Clin Oncol 5: 77
8. Bitran J, Kaminer L, Williams S (1989) High dose chemotherapy with autologous hematopoietic stem cell rescue in stage IV breast cancer: the University of Chicago experience. In: Dicke K, Spitzer G, Jagannath S, Evinger-Hodges M (eds) Autologous bone marrow transplantation; proceedings of the fourth international symposium. University of Texas MD Anderson Cancer Center, Houston, p 367
9. Bonnadona G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10
10. Booser DJ, Hortobagyi GN (1992) Treatment of locally advanced cancer. Semin Oncol 19 [Suppl 3]: 278
11. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M (1991) Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9: 2134
12. Campora E, Pronzato P, Amoroso D, Bertelli GF, Venturini M, Baldini E, Brunetti I, Sertoli MR, Conte P, Rosso R (1992) Prognostic factors in positive primary breast cancer patient treated with adjuvant CMF. Anticancer Res 12: 1555
13. Carmo-Pereira J, Costa FO, Henriques E, Godinho F, Cantinho-Lopes MG, Sales-Luis A, Rubens RD (1987) A comparison of two doses of Adriamycin in the primary chemotherapy of disseminated breast carcinoma. Br J Cancer 56: 471
14. Cocconi G, Algeri R, Contu A, Dalla Palma M, Di Blasio B, Di Costanzo F, Pailla G, Fosser, V, Gebbia V, Moretti G, Palmeri S, Sabbatini R, Buzzi P (1994) Randomized trial of conventional vs a more intensive sequential chemotherapy as adjuvant treatment in stage II breast carcinoma with > 10 involved axillary nodes (abstract). Proc Am Soc Clin Oncol 13: 62
15. Dimitrov N, Anderson S, Fisher B, Redmond C, Wickerham DL, Pugh R, Spurr C, Goodnight J Jr, Abramson N, Wolter J (1994) Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): findings from NSABP B-22 (abstract). Proc Am Soc Clin Oncol 13: 64
16. Donegan WL, Padrta B (1990) Combined therapy for inflammatory breast cancer. Arch Surg 125: 578
17. Dunphy FR, Spitzer G (1992) Use of very high dose chemotherapy with autologous bone marrow transplantation in treatment of breast cancer. J Natl Cancer Inst 84: 128
18. Dunphy F, Spitzer HG, Buzdar A, Hortobagyi G, Howitz L, Yau J, Spinolo J, Jagannath S, Dicke K (1989) High-dose therapy with ABMT in metastatic breast cancer/clinical features of prolonged progression-free survival (abstract). Proc Am Soc Clin Oncol 8: 25
19. Dunphy FR, Spitzer G, Dicke K Buzdar A. Hortobagyi G (1989): Tandem high-dose chemotherapy as intersification in stage IV breast cancer. In: Bone Marrow Transplantation: Current controversis. New York, Alan R Liss pp 245-251
20. Dunphy FR, Spitzer G, Fornoff JER, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN (1994) Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 73: 2157
21. Eddy D (1992) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10: 657
22. Eder JP, Antman K, Peters W, Henner WD, Elias A, Shea T, Schryber S, Andersen J, Come S, Schnipper L (1986) High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 4: 1592
23. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR (1986) Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578
24. Fields KK, Elfenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC (1993) Two novel high dose treatment regimens for metastatic breast cancer - ifosfamide, carboplatin plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Semin Oncol 20 [Suppl 5]: 59
25. Fisher B, Bauer M, Wickerman DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. Cancer 52: 1551
26. Forastiere AA, Hakes TB, Wittes JT, Wittes RE (1982) Cisplatin in the treatment of metastatic breast carcinoma: a prospective randomized trial of two dosage schedules. Am J Clin Oncol 5: 243
27. Frei E III, Canellos GP (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585
28. French Epirubicin Study Group (1991) A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 9: 305
29. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Luini A, Greco M, Zucali R, Valagussa P, Bonadonna G (1992) Growth factor-supported high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with *10 positive nodes (abstract). Proc Am Soc Clin Oncol 11: 60
30. Grad G, Lane N, Zimmerman T (1994) High dose chemotherapy and autologous stem cell support in metastatic breast cancer: the University of Chicago experience (abstract). Proc Am Soc Clin Oncol 13: 73
31. Griswold DP Jr, Trader MW, Frei E III, Peters WP, Wolpert MK, Laster WR Jr (1987) Response of drug-sensitive and resistant L-1210 leukemias to high-dose chemotherapy. Cancer Res 47: 2323
32. Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye SB, Soukop M, Symonds RP, Reed NS, Rankin EM (1991) Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 9: 295
33. Henderson IC, Hayes DF, Gelman R (1988) Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol 6: 1501
34. Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thigpen T, Braine H (1976) Combination chemotherapy and Adriamycin in patients with advanced breast cancer. Cancer 38: 13
35. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, Smith TL, Blumenschein GR, Yap HY, Rodriguez V (1987) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 5: 354
36. Hortobagyi GN, Frye D, Buzdar AU (1988) Complete remissions in metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 7: 37
37. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4: 1162
38. Jones RB, Shpall EJ, Ross M, Bast R, Affronti M, Peters WP (1990) AFM induction chemotherapy, followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer. Current results (abstract). Proc Am Soc Clin Oncol 9: 9
39. Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, Iglehart JD, Moore J, Gockerman J, Bast RC, Peters WP (1990) The Duke AFM programme: intensive induction chemotherapy for metastatic breast cancer. Cancer 66: 431
40. Kennedy MJ, Beveridge R, Rowley SD, Jones R, Yearger A, Wagner J, Saral R, Damron D, Abeloff M, Davidson NE (1989) High dose consolidation chemotherapy and rescue with purged autologous bone marrow following dose-intense induction for metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 8: 19
41. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE (1991) High dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83: 920
42. Livingston RB, Schulman S, Griffin BR, Tranum BL, Rivkin SE, Goldberg RS, Fabian CJ, Hammond N, Hynes H (1987) Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. Cancer 59: 1249
43. Livingston R, Collins C, Williams M, Thompson T, Rivkin S (1994) Determinants of outcome after consolidation for stage IV breast cancer with cyclophosphamide, etoposide and cisplatin (abstract). Proc Am Soc Clin Oncol 13: 58
44. Malik R, Blumenschein GR, Legha SS, Hortobagyi GN, Buzdar A, Yap HY, Hill S, Bodey GP (1982) A randomized trial of high-dose 5-fluorouracil (F), doxorubicin (A), and cyclophosphamide (C) vs conventional FAC regimen in metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 1: 79
45. Maloisel F, Dufour P, Bergerat JP, Herbrecht R, Duclos B, Boilletot A, Giron C, Jaeck D, Haennel P, Jung G, Oberling F (1990) Results of initial doxorubicin, 5-fluorouracil and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 65: 851
46. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP (1980) Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45: 2917
47. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B (1977) Dose response evaluation of Adriamycin in human neoplasia. Cancer 39: 1940
48. Overmoyer B, Dannley R, Goormastic M, Andresen S, Lichtin A, Bolwell B (1994) Consolidation for high risk breast cancer with high dose chemotherapy and autologous bone marrow rescue (abstract). Proc Am Soc Clin Oncol 13: 93
49. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO (1988) High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368
50. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB (1993) High dose chemotherapy and autologous bone marrow support as consolidation after standard dose adjuvant therapy for high risk primary breast cancer. J Clin Oncol 11: 1132
51. Pinedo HM (1993) Dose effect relationship in breast cancer. Ann Oncol 4: 351
52. +) breast cancer: which patients (PTS) are at high risk (abstract)? Proc Am Soc Clin Oncol 10: 59
53. Roché H, Chevreau C, Mihura J, Facchini T, Skaf R, Marre A, Reme JM, Bugat R (1994) Intensive induction chemotherapy (FEC-HD), then high dose chemotherapy with autologous bone marrow transplantation as treatment for non metastatic inflammatory breast cancer (abstract). Proc Am Soc Clin Oncol 13: 89
54. Schwartzberg L, Birch R, Hazelton B, Tauer K, Kalman L, Ross A, Raefsky E, Wittlin F, Schnell F, West W (1994) High dose chemotherapy with peripheral blood stem cell support for high risk stage II and stage III breast cancer (abstract). Proc Am Soc Clin Oncol 13: 97
55. Skipper HE, Schabel FM Jr (1984) Tumor stem cell heterogeneity: implication with respect to the classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 43
56. Slease RB, Benear JB, Selby GB, Reitz CL, Hughes WL, Watkins CL, Epstein RB (1988) High dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 6: 1314
57. Slease RB, Selby GB, Saez RA, Strand C, Bernear JB, Geister B, Epstein RB (1990) Autologous bone marrow transplantation (ABMT) for metastatic breast carcinoma in complete or partial remission (abstract). Proc Am Soc Clin Oncol 9: 13
58. Sledge GW, Loesch D, Lottisch C (1993) Two cycles of high dose chemotherapy with autologous bone marrow rescue as initial therapy for stage IIIB breast cancer (abstract). Breast Cancer Res Treat 18: 182
59. Steel GG (1977) Growth kinetics of tumors: Cell population kinetics in relation to the growth and treatment of cancer. Oxford. Clarendon Press, p. 244
60. Swain SN, Lippman ME (1989) Treatment of patients with inflammatory breast cancer. In: De Vita VT, Hellman S, Rosenberg S (eds) Important advances in oncology. Lippincott, Philadelphia, p 129
61. Tajima T, Tokuda Y, Otha M (1988) High-dose chemotherapy supported by autologous bone marrow transplantation in solid tumors. Tokai J Exp Clin Med 8: 41
62. Tajima T, Sonoda H, Kubnota M (1983) High dose combination chemotherapy with autologous bone marrow transplantation in breast carcinoma. Jpn J Cancer Chemother 10: 840
63. Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6: 1377
64. Van der Graaf WTA, Willemse PHB, Sleijfer DT, Vries EGE de, Mulder POM, Ploeg E van der, Dolsma WV, Mulder NH (1993) Intensive chemotherapy with autologous bone marrow reinfusion in premonopausal breast cancer patients with over 5 positive lymph nodes (abstract). Breast Cancer Res Treat 18: 184
65. Vaughan WP (1993) Autologous bone marrow transplantation in the treatment of breast cancer: clinical and technologic strategies. Semin Oncol 20 [Suppl 5]: 55
66. Vaughan WP, Reed EC, Edwards B, Kessinger A (1994) High-dose cyclophosphamide, thiotepa, and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemo-therapy regimen for early metastatic breast cancer. Bone Marrow Transplant 13: 619
67. Vincent MD, Powles TJ, Coombes RC, McElwain TJ (1988) Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 21: 255
68. Willemse PH, Mulder NH, Sleijfer DT (1991) Intensive ablative chemotherapy with autologous bone marrow rescue in patients with locally advanced breast cancer in complete remission (abstract). Eur J Cancer 27: S39
69. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD (1989) High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7: 1824
70. Williams SF, Gilewski T, Mick R, Bitran JD (1992) High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 10: 1743
71. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E III, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253